Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295815 · ClinicalTrials.gov registry record · Phase 3
Enzastaurin Versus Lomustine in Glioblastoma
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 397
- Enrollment target
NCT00295815 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 397 participants.
The verdict
NCT00295815, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 397 participants
- Enrollment target
Study Summary
This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).
Interventions
- DRUG lomustine
- DRUG enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2006-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295815
The ClinicalTrials.gov registry entry for NCT00295815 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lomustine is the first listed.
NCT00295815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295815 about?
NCT00295815 is a clinical study titled "Enzastaurin Versus Lomustine in Glioblastoma". This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).
What is the current status of trial NCT00295815?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 397 participants. The study started on 2006-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00295815?
The interventions under investigation include: lomustine (DRUG), enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00295815?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.